Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per-Anders Abrahamsson

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Journal of Andrology|June 30, 2004
Cystatin C is highly expressed in the human male reproductive systemThomas Jiborn, Magnus Abrahamson, Hanna Wallin, et al.
Urologic Oncology|December 12, 2002
Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell linesNishtman Dizeyi, Lutz Konrad, Anders Bjartell, et al.
European Urology Focus|July 30, 2017
Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation TherapyPer-Anders Abrahamsson, Laurent Boccon-Gibod, Juan Morote, et al.
European Urology|July 17, 2013
Early detection of prostate cancer: European Association of Urology recommendationAxel Heidenreich, Per-Anders Abrahamsson, Walter Artibani, et al.
Scandinavian Journal of Urology and Nephrology. Supplementum|July 16, 2005
Prognostic value of serum markers for prostate cancerUlf-Håkan Stenman, Per-Anders Abrahamsson, Gunnar Aus, et al.
The Prostate|May 6, 2008
Hormonal regulation of beta2-adrenergic receptor level in prostate cancerHåkon Ramberg, Turid Eide, Kurt Allen Krobert, et al.
European Urology|May 1, 2013
Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trialsAlessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2007
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 yearsHans Lilja, David Ulmert, Thomas Björk, et al.
European Urology|October 18, 2011
Current vaccination strategies for prostate cancerSteven Joniau, Per-Anders Abrahamsson, Joaquim Bellmunt, et al.
Journal of Diabetes Research|August 22, 2015
Influence of Melatonin on the Proliferative and Apoptotic Responses of the Prostate under Normal and Hyperglycemic ConditionsMarina G Gobbo, Nishtman Dizeyi, Per-Anders Abrahamsson, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Journal of Andrology|June 30, 2004
Cystatin C is highly expressed in the human male reproductive systemThomas Jiborn, Magnus Abrahamson, Hanna Wallin, et al.
Urologic Oncology|December 12, 2002
Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell linesNishtman Dizeyi, Lutz Konrad, Anders Bjartell, et al.
European Urology Focus|July 30, 2017
Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation TherapyPer-Anders Abrahamsson, Laurent Boccon-Gibod, Juan Morote, et al.
European Urology|July 17, 2013
Early detection of prostate cancer: European Association of Urology recommendationAxel Heidenreich, Per-Anders Abrahamsson, Walter Artibani, et al.
Scandinavian Journal of Urology and Nephrology. Supplementum|July 16, 2005
Prognostic value of serum markers for prostate cancerUlf-Håkan Stenman, Per-Anders Abrahamsson, Gunnar Aus, et al.
The Prostate|May 6, 2008
Hormonal regulation of beta2-adrenergic receptor level in prostate cancerHåkon Ramberg, Turid Eide, Kurt Allen Krobert, et al.
European Urology|May 1, 2013
Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trialsAlessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2007
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 yearsHans Lilja, David Ulmert, Thomas Björk, et al.
European Urology|October 18, 2011
Current vaccination strategies for prostate cancerSteven Joniau, Per-Anders Abrahamsson, Joaquim Bellmunt, et al.
Journal of Diabetes Research|August 22, 2015
Influence of Melatonin on the Proliferative and Apoptotic Responses of the Prostate under Normal and Hyperglycemic ConditionsMarina G Gobbo, Nishtman Dizeyi, Per-Anders Abrahamsson, et al.
Pageof 6